Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee - 22/04/20
, Rox Anderson, MD b, Fran Cook-Bolden, MD c, Zoe Draelos, MD d, Richard L. Gallo, MD, PhD e, Richard D. Granstein, MD f, Sewon Kang, MD g, Marian Macsai, MD h, Linda Stein Gold, MD i, Jerry Tan, MD jAbstract |
In 2017, a National Rosacea Society Expert Committee developed and published an updated classification of rosacea to reflect current insights into rosacea pathogenesis, pathophysiology, and management. These developments suggest that a multivariate disease process underlies the various clinical manifestations of the disorder. The new system is consequently based on phenotypes that link to this process, providing clear parameters for research and diagnosis as well as encouraging clinicians to assess and treat the disorder as it may occur in each individual. Meanwhile, a range of therapies has become available for rosacea, and their roles have been increasingly defined in clinical practice as the disorder has become more widely recognized. This update is intended to provide a comprehensive summary of management options, including expert evaluations, to serve as a guide for tailoring treatment and care on an individual basis to achieve optimal patient outcomes.
Le texte complet de cet article est disponible en PDF.Key words : drugs, erythema, flushing, lasers, lifestyle, management, ocular, papules, phenotypes, phymatous, pustules, rosacea, telangiectasia, therapy, utility
Abbreviation used : NRS
Plan
| Funding sources: Supported by the National Rosacea Society. The National Rosacea Society has been funded by donations from patients and corporations, including Aclaris Therapeutics, Allergan, Bayer, Cutanea Life Sciences, Inc, and Galderma Laboratories, LP. No corporate donor to the National Rosacea Society was involved in any aspect of this report, nor did any corporate donor or related agency contribute to its review or content. |
|
| Conflicts of interest: Dr Thiboutot is a Galderma consultant. Dr Cook-Bolden is an investigator for Cutanea and Foamix and an advisory board member and consultant for Galderma. Dr Draelos is an investigator for BioPharmX, SolGel, Foamix, Galderma, Allergan, and Hovione. Dr Gallo is cofounder of MatriSys Bioscience and is an advisory board member for MatriSys and Sente Inc. Dr Granstein is an Elysium advisory board member. Dr Stein Gold is a speaker for Galderma and Aclaris, a consultant for Galderma, and an investigator for Galderma, Sol-Gel, and Foamix. Dr Tan is an advisory board member for Galderma, Promius, and Sun, and a speaker, investigator, and consultant for Galderma. Drs Anderson, Kang, and Macsai have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprint requests: National Rosacea Society, 196 James St, Barrington, IL 60010. E-mail: Info@rosacea.org |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?